BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...cells are in preclinical development. EPV-CoV-19 in development at EpiVax Therapeutics Inc. was designed using EpiVax Inc.’s...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...NASDAQ:EDIT) hired Gad Berdugo as CBO, a new position. He was co-founder and CEO of EpiVax...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...to $190.5 million in milestones, plus royalties. EpiVax shortens time to produce personalized cancer vaccines EpiVax...
BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...of high-risk HPV strains in early 2021. Cancer immunotherapy company EpiVax Oncology Inc. , an EpiVax Inc....
BioCentury | Oct 23, 2018
Company News

Management tracks: Celgene, Seres, AC Immune

...of U.S. oncology strategy, partnering and operations at Novartis AG (NYSE:NVS; SIX:NOVN). Cancer immunotherapy company EpiVax...
BioCentury | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

...said they were unaware of the planned entertainment, including Xencor Inc. (NASDAQ:XNCR); Nanobiotix S.A. (Euronext:NANO); EpiVax Inc....
BioCentury | Feb 1, 2016
Company News

EpiVax, Schroedinger deal

...develop a portfolio of “biobetter” therapeutics that will be “immune-engineered” by EpiVax. Aceno will combine EpiVax’s...
...that it is developing and expects two to reach proof of concept within 10 years. EpiVax Inc....
BioCentury | Dec 22, 2014
Company News

EpiVax, Chugai deal

...EpiVax granted Chugai rights to use EpiVax’s Interactive Protein Screening and Reengineering Interface (IPSRI) and OptiMatrix...
...partial and complete sequences of protein therapeutic candidates. The companies did not respond to questions EpiVax Inc....
BioCentury | Dec 9, 2013
Company News

Biotest, EpiVax deal

...Biotest and EpiVax partnered to develop a non-immunogenic Factor VIII therapy to treat hemophilia. The partners...
...partnered to develop a non-immunogenic Factor VIII therapy to treat hemophilia. The partners will use EpiVax's...
...immune response to drugs. The companies declined to disclosed details. Biotest AG (Xetra:BIO), Dreieich, Germany EpiVax Inc....
BioCentury | Feb 18, 2013
Company News

EpiVax, Novozymes deal

...The companies will combine EpiVax's Tregitope technology with Novozymes' Albufuse albumin-based half-life extension technology to develop...
...the activity of regulatory T cells to potentially reduce a patient's immune response to drugs. EpiVax...
...the deal and Novozymes will be eligible for royalties. The companies declined to disclose details. EpiVax Inc....
Items per page:
1 - 10 of 16
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...cells are in preclinical development. EPV-CoV-19 in development at EpiVax Therapeutics Inc. was designed using EpiVax Inc.’s...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...NASDAQ:EDIT) hired Gad Berdugo as CBO, a new position. He was co-founder and CEO of EpiVax...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...to $190.5 million in milestones, plus royalties. EpiVax shortens time to produce personalized cancer vaccines EpiVax...
BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...of high-risk HPV strains in early 2021. Cancer immunotherapy company EpiVax Oncology Inc. , an EpiVax Inc....
BioCentury | Oct 23, 2018
Company News

Management tracks: Celgene, Seres, AC Immune

...of U.S. oncology strategy, partnering and operations at Novartis AG (NYSE:NVS; SIX:NOVN). Cancer immunotherapy company EpiVax...
BioCentury | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

...said they were unaware of the planned entertainment, including Xencor Inc. (NASDAQ:XNCR); Nanobiotix S.A. (Euronext:NANO); EpiVax Inc....
BioCentury | Feb 1, 2016
Company News

EpiVax, Schroedinger deal

...develop a portfolio of “biobetter” therapeutics that will be “immune-engineered” by EpiVax. Aceno will combine EpiVax’s...
...that it is developing and expects two to reach proof of concept within 10 years. EpiVax Inc....
BioCentury | Dec 22, 2014
Company News

EpiVax, Chugai deal

...EpiVax granted Chugai rights to use EpiVax’s Interactive Protein Screening and Reengineering Interface (IPSRI) and OptiMatrix...
...partial and complete sequences of protein therapeutic candidates. The companies did not respond to questions EpiVax Inc....
BioCentury | Dec 9, 2013
Company News

Biotest, EpiVax deal

...Biotest and EpiVax partnered to develop a non-immunogenic Factor VIII therapy to treat hemophilia. The partners...
...partnered to develop a non-immunogenic Factor VIII therapy to treat hemophilia. The partners will use EpiVax's...
...immune response to drugs. The companies declined to disclosed details. Biotest AG (Xetra:BIO), Dreieich, Germany EpiVax Inc....
BioCentury | Feb 18, 2013
Company News

EpiVax, Novozymes deal

...The companies will combine EpiVax's Tregitope technology with Novozymes' Albufuse albumin-based half-life extension technology to develop...
...the activity of regulatory T cells to potentially reduce a patient's immune response to drugs. EpiVax...
...the deal and Novozymes will be eligible for royalties. The companies declined to disclose details. EpiVax Inc....
Items per page:
1 - 10 of 16